Alimera (ALIM), pSivida (PSDV) Move Higher as Journal Questions Lucentis Effectiveness

Go back to Alimera (ALIM), pSivida (PSDV) Move Higher as Journal Questions Lucentis Effectiveness

Alimera (ALIM) Receives CRL for ILUVIEN, FDA Rejects NDA Due to Insufficient Safety

November 11, 2011 12:09 PM EST

Alimera Sciences, Inc., (Nasdaq: ALIM) today announced that it has received a complete response letter from the U.S. FDA in response to the New Drug Application for ILUVIEN for the treatment of diabetic macular edema associated with diabetic retinopathy.

The FDA stated that it was unable to approve the ILUVIEN New Drug Application because the New Drug Application did... More